The stock has a 36-month beta value of 1.42. Opinions on the stock are mixed, with 9 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APGE is 37.32M, and at present, short sellers hold a 27.20% of that float. On June 12, 2025, the average trading volume of APGE was 698.04K shares.
APGE) stock’s latest price update
The stock price of Apogee Therapeutics Inc (NASDAQ: APGE) has jumped by 1.00 compared to previous close of 42.02. Despite this, the company has seen a gain of 16.27% in its stock price over the last five trading days. zacks.com reported 2025-06-09 that The average of price targets set by Wall Street analysts indicates a potential upside of 129.1% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
APGE’s Market Performance
Apogee Therapeutics Inc (APGE) has experienced a 16.27% rise in stock performance for the past week, with a 7.23% rise in the past month, and a 10.15% rise in the past quarter. The volatility ratio for the week is 4.57%, and the volatility levels for the past 30 days are at 3.20% for APGE. The simple moving average for the past 20 days is 8.53% for APGE’s stock, with a -3.31% simple moving average for the past 200 days.
Analysts’ Opinion of APGE
Many brokerage firms have already submitted their reports for APGE stocks, with Citigroup repeating the rating for APGE by listing it as a “Buy.” The predicted price for APGE in the upcoming period, according to Citigroup is $95 based on the research report published on March 13, 2025 of the current year 2025.
Canaccord Genuity, on the other hand, stated in their research note that they expect to see APGE reach a price target of $89. The rating they have provided for APGE stocks is “Buy” according to the report published on November 25th, 2024.
BofA Securities gave a rating of “Buy” to APGE, setting the target price at $80 in the report published on May 10th of the previous year.
APGE Trading at 14.93% from the 50-Day Moving Average
After a stumble in the market that brought APGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.17% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at APGE starting from Dambkowski Carl, who sale 2,725 shares at the price of $36.96 back on Jun 04 ’25. After this action, Dambkowski Carl now owns 241,723 shares of Apogee Therapeutics Inc, valued at $100,716 using the latest closing price.
Dambkowski Carl, the Chief Medical Officer of Apogee Therapeutics Inc, sale 2,725 shares at $35.75 during a trade that took place back on May 07 ’25, which means that Dambkowski Carl is holding 244,448 shares at $97,419 based on the most recent closing price.
Stock Fundamentals for APGE
The total capital return value is set at -0.35. Equity return is now at value -27.85, with -26.71 for asset returns.
Based on Apogee Therapeutics Inc (APGE), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -15.91.
Currently, EBITDA for the company is -216.87 million with net debt to EBITDA at 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.82.
Conclusion
To sum up, Apogee Therapeutics Inc (APGE) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
